Clinical Trials in Coimbatore, India

7 recruiting

Showing 19 of 9 trials

Recruiting
Phase 3

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Heart Failure and Impaired Kidney Function
AstraZeneca4,800 enrolled842 locationsNCT06307652
Recruiting
Phase 2

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca1,160 enrolled363 locationsNCT07082738
Recruiting
Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Phase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Asthma
AstraZeneca540 enrolled208 locationsNCT06932263
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca990 enrolled297 locationsNCT06883305
Recruiting
Phase 2

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Ulcerative Colitis
Eli Lilly and Company252 enrolled147 locationsNCT07186101
Recruiting
Phase 4

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

Asthma
Sanofi1,324 enrolled250 locationsNCT05097287
Recruiting
Phase 2

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B Cell Lymphoma
Karyopharm Therapeutics Inc244 enrolled176 locationsNCT02227251
Recruiting
Phase 4

Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

End-stage Kidney Disease
University of Sydney50,000 enrolled264 locationsNCT02823821